Johns Hopkins biomedical engineers have teamed up with clinicians to create a new drug-delivery strategy for a type of central vision loss caused by blood vessel growth at the back of the eye, where such growth should not occur.
Topical formulation identified for prolonged graft survival in corneal transplants
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of therapies that modulate the immune system to treat cancer, infectious diseases, transplant rejection, autoimmune and inflammatory diseases, has ann…
Health Canada approves JETREA® for the treatment of symptomatic vitreomacular adhesion
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, has announced that Health Canada has approved JETREA(R) (ocriplasmin) for the treatment of sym…
Critical role discovered for the complement system in early macular degeneration
In a study published on line in the journal Human Molecular Genetics, Drs…
Study shows complement activation plays an important role in inherited macular degeneration
In a study published on line this week in the journal Human Molecular Genetics, Drs. Donita Garland, Rosario Fernandez-Godino, and Eric Pierce of the Ocular Genomics Institute at the Massachusetts Eye and Ear, Harvard Medical School, along with their c…
Structure of Polypoidal Choroidal Vasculopathy Studied by Colocalization Between Tomographic and Angiographic Lesions – Corrected Proof
Purpose: To investigate the structure of polypoidal choroidal vasculopathy (PCV) by tomographic localization of the branching vascular network and late geographic hyperfluorescence.Design: Observational case series.Methods: We examined 34 eyes with PCV…